Abstract
Inotuzumab ozogamicin is a humanized anti-CD22 monoclonal antibody bound to a toxic natural calicheamicin, which is under investigation for the treatment of relapsed/refractory acute lymphoblastic leukemia. CD22 is commonly expressed in 90-100% of malignant mature B-lymphocyte lineage. The first Phase II study with inotuzumab ozogamicin conducted by Kantarjian et al. gave the opportunity for heavily pretreated patients with acute lymphoblastic leukemia to go for allogeneic stem cell transplant. Inotuzumab is well-tolerated with the exception of veno-occlusive disease. Overall inotuzumab ozogamicin is potentially an encouraging and promising therapy for patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 135-143 |
| Number of pages | 9 |
| Journal | Immunotherapy |
| Volume | 8 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2016 |
Keywords
- acute lymphoblastic leukemia
- antibody drug conjugate
- inotuzumab
- monoclonal antibody
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology
Fingerprint
Dive into the research topics of 'Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS